ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

User Fees Proposed For FDA Oversight Services; Industry Groups Call It “Tax On Innovations”

January 20, 1989

Progress Reported On Zinder Recommendations for Virus Program

July 4, 1975

In Brief: Middle East Cancer Consortium Formed; Armitage, Mayer Elected To ASCO Positions

May 24, 1996

Smoking Conference Established Priorities

January 15, 1982

National Dialogue plans biospecimen network

July 18, 2003

Study: Negative HPV Test More Accurate than Negative Pap Test In Predicting Cervical Cancer Risk

July 25, 2014